CDMO

R&D

Patient central focus of an HCP in the therapy journey

More than manufacturing: The value of a patient-centric CDMO

For a biopharmaceutical company, contracting a CDMO that considers itself accountable to the patients can deliver a tangibly different experience.

R&D

Bringing therapies to patients quicker with integrated CDMO ...

Biotechs and pharmaceutical companies can receive enormous value from a trusted partnership with an integrated CDMO and CRO.

Sales & Marketing

Solution Spotlight: Accelerator Drug Development

Thermo Fisher Scientific’s Accelerator Drug Development is a suite of integrated services combining CDMO and CRO to streamline drug development.

News

Novo completes $16.5bn takeover of Catalent

Novo Holdings' $16.5bn takeover of US CDMO Catalent has been completed, after months of debate over potential antitrust issues.

News

Halozyme abandons its €2bn pursuit of Evotec

Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations

News

Nick Green, president and CEO of Avid Bioservices

Avid Bioservices to go private in $1.1bn private equity deal

Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part

More than manufacturing: The value of a patient-centric CDMO

Bringing therapies to patients quicker with integrated CDMO ...

Solution Spotlight: Accelerator Drug Development

Novo completes $16.5bn takeover of Catalent

Halozyme abandons its €2bn pursuit of Evotec

Avid Bioservices to go private in $1.1bn private equity deal

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

CDMO

Editor's Picks